Abeona TherapeuticsABEO
Recorded

Abeona Therapeutics Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration33 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Steven WilleySenior Biotech Analyst

All right. We're going to go ahead and get started. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel, and glad to have with us in the next session, Abeona Therapeutics. We have CEO Vish Seshadri. Did I say that correctly?

Vish SeshadriCEO

Absolutely. All right. Thanks for having us.

Steven WilleySenior Biotech Analyst

Madhav, I always We'll get there.

Steven WilleySenior Biotech Analyst

All right. Madhav is the Chief Commercial Officer, and then Joe Vazzano, who's a much easier name to pronounce, on the end. Vish is going to go through a few slides. I think that's somewhat intended to provide a recap, but also to provide just a little bit of perspective on the asset acquisition that was just done. We'll have some time for Q&A. If anyone has a question, feel free to raise your hand, and we'll get you acknowledged and hopefully your question answered. So Vish, I'm going to turn it over to you.

Vish SeshadriCEO

Thank you. Thank you very much, Stephen.

Vish SeshadriCEO

Good morning, everybody. It's a pleasure to be here. I have a few slides, which I'll try to cover in about 10, 15 minutes, and then we'll have ample time for Q&A after that. For those of you, before I get into the slide deck itself, just want to remind everyone that there'll be forward-looking statements in my presentation today, as well as in the discussions, as always. For those new to the story of Abeona, we are a commercial-stage rare disease company. We launched ZEVASKYN, which was FDA approved in 2025. We launched it in December with the first patient treated then. We're building a very solid foundation for this launch, which I'll talk about in a little bit.

Vish SeshadriCEO

Also, as part of bringing ZEVASKYN to approval, as well as FAYUVI, which we licensed out to Ultragenyx, those experiences have given us strong capabilities in the development side of things as well. Our goal as a company is really to build a diversified, long-term revenue-generating business and sustain that long-term growth and expand on margins. Just a quick recap of what we shared yesterday, quarter three results. Importantly, this is the fourth quarter since we treated the first patient. So, we're seeing slow but steady growth in numbers. We've treated six patients in the third quarter. Also, that amounts to about, sums up to 15 patients since launch last year. When we started commercialization and entered 2026, only two sites were actively taking on patient biopsies, and that's the case until quarter two.

Vish SeshadriCEO

Quarter three, we also announced that the third and the fourth sites, which are CHOP and UTMB, have completed their first treatments. This is a very important milestone for a site because this is the validation of a site having been through the end-to-end process of taking a patient all the way to treatment, and that doesn't happen lightly. There's a lot of work that goes into that, and then it becomes easier and easier as they repeat this for the second, third patient, and so on. Now we have eight QTCs activated across the U.S., of which four have treated their patients. If you look at this map here, you can really see how geographically these sites are positioned to give patients access to treatment centers without having to travel an inordinate amount of length of distance.

Vish SeshadriCEO

This is something that they do to get their care on a routine basis. These are centers of excellence that have cared for many, many years and decades for EB patients. While the commercial foundation for this launch has been laid, and we are not stopping here, sites that are EB care centers that have the right capabilities to apply ZEVASKYN to their patients, we are still continuing to engage with such sites and exploring possibilities that they could be QTC. So we're not stopping with this footprint that we are showing here right now. As we scale the commercial launch, we don't want to forget the fact that we have strong capabilities in drug development. I gave you the example of FAYUVI.

Vish SeshadriCEO

We dosed all the patients clinically, and we also had agreement with the FDA about the primary endpoint, the Bayley-III, before we licensed the drug to Ultragenyx. That was approved in September this year. We have also licensed our other asset to Taysha for Rett syndrome. So we have development experience as well. One of our goals was to build our late-stage pipeline, which currently looks barren, and that's what brings us to this new chapter that we announced yesterday with the acquisition of ABO-801, which was previously called APT-1011. This is an orphan drug, and it has a very compelling differentiation in the market in the disease therapeutic area that it serves, which is eosinophilic esophagitis, EoE in short.

Vish SeshadriCEO

The important characteristics or properties of this asset that made us look at it seriously and get to the stage of bringing it on board are, one, it's not just a late-stage phase III-ready asset. It has a robust established clinical foundation with the data that has been generated through two phase III studies. The data look very encouraging, despite the fact that one of the co-primary endpoints was missed in those studies. I'll get into the weeds of that a little bit because that's the crux of the argument that why a next phase III study is stacked better, right? The compelling differentiation, if you look at the marketplace of EoE, there are oral corticosteroids, and then there are injectables, which are mostly biologics.

Vish SeshadriCEO

There's a lot of innovation happening on the biologics side, whether it's IL-4, IL-13, TSLPs, various targets, and these are all systemic drugs. That bucket has a lot of emerging therapies and innovation, and that market is going to play out. But in the oral-corticosteroid market, there's very little innovation happening. There's only one approved drug, EOHILIA. So, there is still a very high unmet need for oral corticosteroids that can overcome some of the limitations of what current therapies have, which also I'll talk about. That brings us to the disease landscape. The reason we have orphan drug status here is because this is a recently discovered disease in the 1990s, so there's not a whole lot of history, but it's rapidly growing. We're estimating that it's about 360,000, and that number may even be obsolete. It may be a bigger number today.

Vish SeshadriCEO

This is a disease that is pretty much definitively diagnosed by a gastroenterologist, because the definitive diagnosis involves looking at the histology of biopsy samples of the esophagus, where you're looking at eosinophils. If it's more than 15 per high-power field, that is the test for a positive EoE diagnosis. So, the call points for this kind of a condition is going to be the GI specialists. The properties of this drug, this drug was designed. Fluticasone propionate is known through many, many years and experience as an anti-allergy drug, but in case of ABO-801, it was specifically designed to treat EoE. It maximizes. It's a pill that dissolves in your tongue in 30 seconds. It's taken bedtime, and it maximizes the deposition of fluticasone locally, pretty much through the entire esophagus.

Vish SeshadriCEO

If you look at biopsies for histological markers in the proximal and distal ends, you see that control of disease across the length of the esophagus. So, that's a very important property, and very less systemic absorption, less than 1% of systemic absorption. So, that is the reason why in the phase III studies, we haven't seen any systemic effects like adrenal suppression, which is important. As I said, the safety profile of this drug is quite favorable because of a local-acting formulation. If you look at the key features, there's a lot of clinical data. We have a clinical history deck in our corporate website, which I'll encourage people to go and take a look when you have time. It gives the history of how the dose was determined and what the two phase III studies looked at.

Vish SeshadriCEO

Importantly, I will tell you about a couple of things. I spoke about the safety features already, but if you look at the efficacy highlights, there are two things that a regulator is going to look at. One is the histological marker. What is the proportion of patients that achieves less than or equal to six eosinophils in the high-power field? That is something that every drug that has come to market has shown, and there's not so much differentiation. This is just table stakes. This is the bare minimum you have to do. Look at any trial, you're going to find numbers in the 50s and 60s of percentages of patients that are in that bucket. If you look at FLUTE-2 and FLUTE-3, you will find answers in the 60s and 50s of percentage.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day